Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based on a price of $638.70 for REGN at the time of writing.

Regeneron Pharmaceuticals Inc. closed 54.89% short of its 52-week high of $1,211.20, which the company reached on August 27th.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President ...

What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.

Investors evidently have re-rated Regeneron from a fast-growth stock to a slow-growth stock, thereby warranting a lower earnings multiple for safety. In this article, I will assess the company’s ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc ... implications of the White House’s stance on the stock market. Here’s what he said: “So, let ...